Not Yet Recruiting
PHASE3
INTERVENTIONAL
NCT07282613
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their blood sugar and body weight. The study has 2 parts: in the first part participant will get either CagriSema or placebo, and in the second part participant will get CagriSema. In the first part, which treatment participant gets is decided by chance and second part is open label and all participants will get CagriSema during this part. The study will last for about 1 year and 3 months.
Interventions
Name:
CagriSema (Cagrilintide B and Semaglutide I)
Type:
DRUG
Description:
Cagrilintide B and Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
Name:
Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Type:
DRUG
Description:
Placebo matched to Cagrilintide B and Placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
Primary Outcomes
Measure:
Change in glycated haemoglobin (HbA1c)
TimeFrame:
From baseline (week 0) to end of double-blinded treatment (week 26)
Description:
Measured as percentage (%) of HbA1c.
Trial Information
NCT ID
NCT07282613
Status
Not Yet Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025